The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.
Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.
Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.
The conversation is about hair loss and the conclusion is that genetics play a significant role in hair loss, and lifestyle choices or being a well-adjusted person do not prevent male pattern baldness.
The conversation is about hair transplants in America, specifically the availability of DHI. The user is currently using finasteride and plans to use microneedling, oral castor oil, and eventually undergo FUE or DHI.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
The post discusses Dr. Rassman's advice on microneedling for hair loss, suggesting holding a Dr Pen with 36 needles in one spot for 10 seconds. The conversation includes differing opinions on this method, with one user explaining the importance of dipping the pen rather than swiping to avoid abrasions.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.